Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan

Press ReleaseNicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan Exclusive Japanese partner Kowa has initiated a Phase 3 safety clinical trial of NCX 470 for the treatment of ocular hypertension in JapanTriggers a €2 million milestone payment to Nicox August 5, 2025 – release at 7:30 am CET Sophia Antipolis, France Nicox SA(Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that its exclusive...

Biot, 05/08/2025 (informazione.news - comunicati stampa - salute e benessere)

Attachment